Gazyva (obinutuzumab) - Roche, Biogen
Columvi (glofitamab-gxbm) - Roche
Lunsumio (mosunetuzumab-axgb) - Roche
UPCC 48420: CAR-T Followed by Bispecific Antibodies (clinicaltrials.gov) - Sep 15, 2026 - P2 | N=23 | Active, not recruiting | Sponsor: Abramson Cancer Center at Penn Medicine | Recruiting ➔ Active, not recruiting 
Enrollment closed • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
http://clinicaltrials.gov/ct2/show/NCT04889716
 
Sep 15, 2026
 
Prev Next